Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes

Documenti analoghi

• Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials
  di: Ying Lu, et al.
  Pubblicazione: (2024)
• Sodium–glucose cotransporter 2 inhibitors reduce the risk of incident type 2 diabetes in people with heart failure without diabetes: An analysis of real‐world, cohort data
  di: Alex E. Henney, et al.
  Pubblicazione: (2024)
• Real‐world effectiveness of sodium‐glucose cotransporter‐2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria
  di: Afif Nakhleh, et al.
  Pubblicazione: (2024)
• Sodium‐glucose cotransporter‐2 inhibitors and subtype‐specific dementia risk: A multinational and multiethnic cohort study
  di: Mingyang Sun, et al.
  Pubblicazione: (2025)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  di: Ryo Suzuki, et al.
  Pubblicazione: (2025)